+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company's marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); a-Glucosidase for the treatment of Pompe disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

Pharming Group NV Key Recent Developments

May 17, 2023: Pharming Group reports on results of the 2023 annual general meeting of shareholders
May 11, 2023: Pharming Group reports financial results for the first quarter of 2023
Apr 05, 2023: Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
Apr 05, 2023: Pharming Group convenes the Annual General Meeting of Shareholders 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Pharming Group NV - Key Facts
  • Pharming Group NV - Key Employees
  • Pharming Group NV - Key Employee Biographies
  • Pharming Group NV - Major Products and Services
  • Pharming Group NV - History
  • Pharming Group NV - Company Statement
  • Pharming Group NV - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Pharming Group NV - Business Description
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Rest of the world (RoW)
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • Pharming Group NV - Corporate Strategy
  • Pharming Group NV - SWOT Analysis
  • SWOT Analysis - Overview
  • Pharming Group NV - Strengths
  • Pharming Group NV - Weaknesses
  • Pharming Group NV - Opportunities
  • Pharming Group NV - Threats
  • Pharming Group NV - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Pharming Group NV, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 17, 2023: Pharming Group reports on results of the 2023 annual general meeting of shareholders
  • May 11, 2023: Pharming Group reports financial results for the first quarter of 2023
  • Apr 05, 2023: Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
  • Apr 05, 2023: Pharming Group convenes the Annual General Meeting of Shareholders 2023
  • Mar 16, 2023: Pharming Group reports financial results for full year 2022
  • Feb 28, 2023: Pharming Group Notice of Full Year 2022 financial results
  • Feb 28, 2023: Notice of Full Year 2022 financial results
  • Oct 27, 2022: Pharming Group reports earnings for the first nine months of 2022
  • Jul 25, 2022: Pharming Group Notice of H1 2022 Results
  • May 18, 2022: Pharming Group: all proposals Annual General Meeting of Shareholders approved
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Pharming Group NV, Key Facts
  • Pharming Group NV, Key Employees
  • Pharming Group NV, Key Employee Biographies
  • Pharming Group NV, Major Products and Services
  • Pharming Group NV, History
  • Pharming Group NV, Other Locations
  • Pharming Group NV, Subsidiaries
  • Pharming Group NV, Key Competitors
  • Pharming Group NV, Ratios based on current share price
  • Pharming Group NV, Annual Ratios
  • Pharming Group NV, Interim Ratios
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Pharming Group NV, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Pharming Group NV, Performance Chart (2018 - 2022)
  • Pharming Group NV, Ratio Charts
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Lannett Co Inc
  • CSL Behring LLC
  • Galapagos NV
  • BioCryst Pharmaceuticals Inc
  • Pharmacyclics LLC
  • BioMarin Pharmaceutical Inc
  • Takeda Pharmaceutical Co Ltd
  • Argenx SE
  • Lannett Co Inc
  • CSL Behring LLC
  • Galapagos NV
  • Dyax Corp
  • rEVO Biologics Inc
  • Crucell NV
  • Argenx SE
  • Pharmacyclics LLC
  • Shire Pharmaceuticals International UC